Surgeon volume, prognosis post-esophageal cancer op linked

January 24, 2013
Surgeon volume, prognosis post-esophageal cancer op linked
For patients with esophageal cancer undergoing resection, surgeon volume, but not hospital volume, is independently associated with prognosis, according to research published online Jan. 7 in the Journal of Clinical Oncology.

(HealthDay)—For patients with esophageal cancer undergoing resection, surgeon volume, but not hospital volume, is independently associated with prognosis, according to research published online Jan. 7 in the Journal of Clinical Oncology.

To examine the influence of hospital and surgeon volume on survival after esophageal , Maryam Derogar, M.D., of the Karolinska Institute in Stockholm, and colleagues conducted a population-based cohort study involving 1,335 patients with esophageal cancer who underwent esophageal resection in 1987 to 2005. Participants were followed for survival until February 2011.

The researchers found that annual hospital volume was not independently associated with overall survival, and after adjustment for hospital clustering effects, hospital volume was not associated with short-term . Mortality occurring at least three months after surgery was significantly reduced with a combination of higher annual and cumulative surgeon volume, with a hazard ratio of 0.78 for surgeons with both annual and cumulative volume above versus below the median. The association persisted after adjustment for hospital and surgeon clustering.

"In conclusion, this large and population-based cohort study provided evidence that long-term survival is independently influenced by surgeon volume but not hospital volume," the authors write.

Explore further: Centralization to fewer surgeons results in better survival after esophageal cancer surgery

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Centralization to fewer surgeons results in better survival after esophageal cancer surgery

January 7, 2013
Patients who undergo surgery for oesophageal cancer have a much greater chance of long term survival if the operation is carried out by a surgeon who has performed this particular operation many times before. This according ...

Hospital volume and surgeon specialty influence patient outcomes

June 15, 2012
Researchers from the Netherlands Cancer Institute wanted to understand if patients undergoing lung cancer resections would benefit from having their procedures performed in a high-volume specialized center. The study, published ...

Surgeon experience affects complication rate of spinal stenosis surgery

June 7, 2012
For patients undergoing surgery for spinal stenosis, the risk of complications is higher when the surgeon performs very few such procedures—less than four per year, suggests a study in the June issue of Neurosurgery, ...

Higher hospital volume more important than surgeon experience in outcome of prostate cancer surgery

May 15, 2012
Older, sicker, high-risk patients who undergo one of the most common treatments for prostate cancer get better results in larger, busier hospitals, according to new research by Henry Ford Hospital.

Pre-op chemoradiotherapy ups survival in esophageal cancer

May 31, 2012
(HealthDay) -- For patients with esophageal or esophagogastric-junction cancer, treatment with neoadjuvant chemoradiotherapy followed by surgical resection is associated with improved survival compared with surgery alone, ...

Recommended for you

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

New immunotherapy approach boosts body's ability to destroy cancer cells

January 12, 2018
Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes ...

Cancer's gene-determined 'immune landscape' dictates progression of prostate tumors

January 12, 2018
The field of immunotherapy - the harnessing of patients' own immune systems to fend off cancer - is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of ...

FDA approves first drug for tumors tied to breast cancer genes

January 12, 2018
(HealthDay)—The U.S. Food and Drug Administration on Friday approved the first drug aimed at treating metastatic breast cancers linked to the BRCA gene mutation.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.